Sonoma Pharmaceuticals
SNOA
21 hedge funds and large institutions have $1.82M invested in Sonoma Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.02% less ownership
Funds ownership: 0.09% → 0.06% (-0.02%)
5% less funds holding
Funds holding: 22 → 21 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
33% less capital invested
Capital invested by funds: $2.73M → $1.82M (-$909K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$117K |
| 2 |
VF
Virtu Financial
New York
|
+$99.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$51.5K |
| 4 |
BA
Bard Associates
Chicago,
Illinois
|
+$35.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$255K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$74K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$41K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$11.7K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$4K |
SNOA Hedge Fund Activity: Q2 2018 in Review
21 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2018, worth a combined $1.82M — down 33% from $2.73M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SNOA and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $117K. The largest seller was Sabby Management, exiting entirely with an estimated $255K sold.
- 21 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2018, down from 22 in Q1 2018.
- Funds reported $1.82M of Sonoma Pharmaceuticals stock for Q2 2018, down 33% quarter-over-quarter.
- 3 funds opened new Sonoma Pharmaceuticals positions in Q2 2018 and 4 closed out, a net change of -1 holder.
- The largest Sonoma Pharmaceuticals buyer in Q2 2018 was Renaissance Technologies, an estimated $117K added.
- The largest Sonoma Pharmaceuticals seller in Q2 2018 was Sabby Management, an estimated $255K sold.
Based on aggregated 13F filings for Q2 2018.